1. Bacterial Vaginosis Treatment Patterns, Associated Complications, and Health Care Economic Burden of Women With Medicaid Coverage in the United States.
- Author
-
Watkins E, Chow CM, Lingohr-Smith M, Lin J, Yong C, Tangirala K, Collins K, Li J, Brooks R, and Amico J
- Subjects
- Pregnancy, Female, Humans, United States epidemiology, Adult, Medicaid, Financial Stress, Health Care Costs, Vaginosis, Bacterial drug therapy, Vaginosis, Bacterial epidemiology, Vaginosis, Bacterial microbiology, Vaginitis, Sexually Transmitted Diseases
- Abstract
Background: Bacterial vaginosis (BV) is a highly prevalent vaginal infection., Objectives: Primary objectives of this study were to examine treatment patterns among female patients with Medicaid coverage who were diagnosed with incident BV, the frequency of BV-associated complications, and health care resource utilization (HCRU) and associated costs of incident BV and its recurrence. Secondary objectives were to identify predictors of total all-cause health care costs and number of treatment courses., Methods: Female patients aged 12-49 years with an incident vaginitis diagnosis and ≥1 pharmacy claim for a BV medication were selected from the Merative MarketScan Medicaid database (2017-2020). Additional treatment courses were evaluated during a ≥12-month follow-up period, in which new cases of BV-associated complications and HCRU and the associated costs were also measured. Generalized linear models were used to identify baseline predictors of total all-cause health care costs and number of treatment courses., Results: An incident vaginitis diagnosis and ≥1 BV medication claim were present in 114 313 patients (mean age: 28.4 years; 48.6% black). During the follow-up, 56.6% had 1 treatment course, 24.9% had 2, 10.2% had 3, and 8.3% had ≥4; 43.4% had BV recurrence. Oral metronidazole (88.5%) was the most frequently prescribed medication. Nearly 1 in 5 had a new occurrence of a BV-associated complication; most (76.6%) were sexually transmitted infections (STIs). Total all-cause and BV-related costs averaged $5794 and $300, respectively, per patient; both increased among those with more treatment courses. Older age, pregnancy, comorbidity, any STIs, postprocedural gynecological infection (PGI), and infertility were predictive of higher total all-cause health care costs, while race/ethnicity other than white was predictive of lower costs. Older age, black race, any STIs, pelvic inflammatory disease, and PGI were predictive of >1 treatment courses., Conclusion and Relevance: The high recurrence of BV represents an unmet need in women's health care and better treatments are necessary., Competing Interests: Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Eren Watkins, Candice Yong, Krishna Tangirala, Kevin Collins, and James Li are employees of Organon. Clifton M. Chow, Roy Brooks, and Jennifer Amico are external consultants for Organon which provided consulting fees in connection with this study and the development of this article. Melissa Lingohr-Smith and Jay Lin are employees of Novosys Health, which received financial support from Organon in connection with this study and the development of this article.
- Published
- 2024
- Full Text
- View/download PDF